Amylin’s “poison put” debt deals were not structured primarily to protect interest and principal payments but to trigger a sudden bulk repayment, according to Professor Michael Roberts of Wharton Business School. Amylin has $900 million in debt which must be paid immediately if there is a change in control of the board. Such a massive repayment could be financial suicide for...
Pharma Industry Archive
May 2009
Shire, the maker of ADHD drugs Adderall XR and Vyvanse had an excellent Q1 but now faces a challenge: Its two top products are threatened by a generic that Teva brought to market on April 2. The company is also persisting in the U.S with its Daytrana ADHD patch, which was forced off the market in Europe following manufacturing problems. The basics: Revenues up 16 percent to $818 million from...
If Schering-Plough wants to know what the future possibly holds for its Nuvaring contraceptive — accused in lawsuits of killing a woman via a thromboembolism — it might want to look at what happened with Johnson & Johnson’s Ortho Evra birth control patch. Mother Jones reports: Since 2001, when the FDA green-lighted NuvaRing, the agency has received reports of at least 300...
The FDA has moved to ban diet aid Hydroxycut after it received 23 reports of serious health problems and one death due to liver failure. The recall points out the ridiculous position of federal law as it relates to diet supplements: Even though the FDA has sweeping powers to ensure the safety of drugs and food through its approval and inspection process, it has almost no power over the...
April 2009 has come and gone, and once again it is time for BNET’s roundup of the top 10 weirdest drug stories of the month. Enjoy! Bayer has a flock of sheep mow its lawn About 1450 sheep grazed Bayer’s Richmond, Calif., campus last nonth, eating 115,000 pounds of grass and weeds. It’s a green thing. Peter Rost to become a TV show? Call it “Law & Order: Off-Label...
AstraZeneca is facing nearly 10,000 lawsuits over claims that the company failed to warn people that its antipyschotic, Seroquel, could give patients diabetes. The update came on news that Seroquel sales actually went up in Q1 2009, rising to $1.1 billion from $1 billion. The company’s statement was bullish on the lawsuits, suggesting it thought it was going to win enough of them to avoid...
It’s Allergan’s worst week ever: Q1 2009 net income was down 58 percent on declining Botox sales; and then the FDA gave Botox a black-box warning AND approved Medicis‘ competing wrinkle-killing drug, Dysport. Allergan’s response? To blame it all on Medicis in a tangled set of statements that seem designed to suggest that everything in the category was just fine until...
- Study Showing Drug Ads Are Linked to Higher Prices Has Flaws
- Bankers Reveal Top Biotech IPO Contenders; New Filer Ironwood Among Them
- Pfizer Got $160M in Tax Money to Build in Connecticut
- Sanofi's Viehbacher Backs Health Reform; May Change Company's Name
- Viagra Now Available Intravenously
- Genzyme Kidney Drug Failed, Too...What Could Possibly Happen Next?
- Peter Pitts' CMPI Targeted Over Anti-Healthcare Reform Video Game
- Why Allergan and Medicis Should Embrace the "Botox Tax" in Senate Health Bill
- Why J&J's Stelara Launch Should Target Dermatologists First
- NHS Loses Fight Over Publication of Antipsychotic Meds Brochures for Kids
- Genzyme's Termeer Got $50M in Compensation Over Last 3 Years; Wife Got Trips to Asia on Corporate Jet
- Merck Gives Snapshot of Combined Company: $47B in Sales; Just $7.6B in Cash
- Why Pfizer Wants Your Car-Sick Dog to Travel on Thanksgiving
- FDA Delays Genzyme's Lumizyme, Manufacturing Problems Blamed
- The Business Conundrums of Trying to Prevent Cancer
- Will FDA Approve MannKind's Insulin Inhaler?
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted
- Hepatitis C Drugs Kill the Virus...and Your Sex Drive
- Microchip Implant to Link Your Health Records, Credit History, Social Security
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching
- NYT's MannKind Story Needlessly Quoted a Competitor Bashing Afresa
- Novartis CEO Sends Emails to 140 Animal Rights Activists:
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low
Subscribe to Pharma blog comments RSS 
- How NOT to Write a Biotech Press Release: Just Ask Epeius
- The 10 Weirdest Drug Stories of the Month
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity"
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted
Industry Transcripts by Seeking Alpha
- How to choose the right insurance carrier for your business
- Real Estate: Prepare your properties to weather what lies ahead
- Technology: Be prepared if part of your global supply chain goes missing
Archives
Recommended Sources
About Pharma Industry
BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.